Search Results for: covid-19
Articles
Vaxxas Initiates Phase 1 Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent Delivered Using High-Density Microarray Patch February 10, 2023
Vaxxas recently announced the initiation of a Phase 1 clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent...MARKET REPORT - Survey Suggests Global Innovation to Recover Much More Quickly Than Expected in 2023 February 9, 2023
After a brief fall in 2022 to a score of 6.5 – the first decline since its inception in 2018 – the index has surged to a record score of 7.4. This sudden recovery in scores over a little more than 8 months bodes extremely well for device and packaging manufacturers in the year ahead, suggesting a strong global recovery in industry outlook and confidence.
Revive Therapeutics Enters Research Collaboration Agreement With PharmaTher for Development of MDMA Transdermal Patch February 3, 2023
Revive Therapeutics Ltd. recently announced it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxymethamphetamine (MDMA) using PharmaTher’s novel microneedle….
Brand New State-of-the-Art Nemera Manufacturing Facility Inaugurated in Poland January 25, 2023
Based in Szczecin, this facility will significantly boost Nemera’s manufacturing capabilities and bring more drug delivery device solutions to patients…..
Alvotech & Bioventure Announce Approval of AVT02 (Adalimumab) as Simlandi in Saudi Arabia January 24, 2023
AVT02 as Simlandi is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure….
Needle-Free Patch Technology for mRNA Vaccines Aims to End Need for Frozen Storage & Improve Access January 17, 2023
CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas have recently signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology in a project….
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis & Discloses Clinical Development Plan January 17, 2023
Kinarus Therapeutics AG recently announced preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral...SPECIAL FEATURE - Outsourcing Analytical Testing – Timelines, Regulations & Biologics Drive the Sector January 17, 2023
Contributor Cindy H. Dubin interviews leading CDMOs to discuss not just their analytical service offerings, but their strategies for meeting regulatory challenges and ensuring faster project timelines.
ROUNDTABLE DISCUSSION - Which Trends Will Have the Most Impact on Drug Development in 2023? January 16, 2023
Contributor Cindy H. Dubin posed this question to life science leaders during a recent roundtable discussion, and one common theme is the focus on sustainability in pharmaceutical development.
CLINICAL TRIALS - The Mission to Increase Diverse Clinical Trial Participation January 16, 2023
Lauren Chazal, MBA, and Keidra Gaston, MBA, believe clinical trials are critical to advancing medical knowledge and new therapeutics; however, it is important that participants in clinical trials represent their entire communities and the potential recipients of new treatments.
HRA Pharma Rare Diseases Registers the first Cushing’s Syndrome Treatment in Colombia January 4, 2023
HRA Pharma Rare Diseases, an affiliate of HRA Pharma, a Perrigo Company, recently announced the registration of the first ever...Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate December 27, 2022
Valneva SE recently announced it has completed rolling submission of the Biologics License Application (BLA) to the US FDA for its...ARMED ONCOLYTIC VIRUSES - Instant Messaging Cancer With a TGF-Beta Trap Carrying Oncolytic Adenovirus November 30, 2022
Bryan Oronsky, MD, PhD, says cancer is a systemic disease, the eradication of which heavily depends on immune responses. In his opinion, to overcome impaired immune cell function and, hence, to increase the responsiveness to CIs likely requires a 3-in-1 therapy.
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients November 30, 2022
Aridis Pharmaceuticals, Inc. recently announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the...Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China November 16, 2022
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunities….
Monopar Announces Encouraging Clinical Data From Ongoing Camsirubicin Phase 1b Trial November 16, 2022
Monopar Therapeutics Inc. recently released encouraging data from its ongoing Phase 1b open-label clinical trial of camsirubicin in advanced soft...Tjoapack Strengthens its Injectables Offering With Addition of Prefilled Syringes Assembly & Packaging Services November 11, 2022
Global pharmaceutical contract packaging organization (CPO), Tjoapack has invested in a new high-speed packaging line for prefilled syringes and vials...IMUNON Enters Technology Evaluation Agreement With Acuitas to Evaluate Placcine Plasmid DNA With Lipid Nanoparticle Delivery System November 10, 2022
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA and protein vaccines….
APEIRON Respiratory Therapies Announces Positive Results From Phase I Trial of Inhaled APN01 November 3, 2022
APEIRON Respiratory Therapies GmbH recently announced positive final results from a Phase 1 clinical trial of inhaled APN01 (alunacedase alfa),...TFF Pharmaceuticals Announces Collaboration With Aptar Pharma to Explore & Develop Intranasal Delivery of Dry Powder Vaccines & Dry Powder Therapeutics November 3, 2022
TFF Pharmaceuticals, Inc. recently announced a collaboration with Aptar Pharma aimed at developing and testing the administration of dry powder vaccines utilizing….
